Department of Emergency Medicine, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey.
Department of Pediatrics, Faculty of Medicine, Cerrahpasa University, Istanbul, Turkey.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Nov;168(4):311-318. doi: 10.5507/bp.2024.016. Epub 2024 May 22.
Sepsis-induced acute kidney injury (AKI) remains a major challenge in intensive care, contributing significantly to morbidity and mortality. Tibolone, known for its neuroprotective and hormonal properties, has not been explored for its potential in AKI management. This study investigates the protective effects of Tibolone and its underlying mechanisms involving Sirtuin-1 (SIRT1) and Yes-Associated Protein (YAP) in a rat sepsis model.
Thirty-six female Wistar albino rats underwent cecal ligation and puncture (CLP) to induce sepsis. They were randomly assigned to control, CLP+Saline, and CLP+Tibolone groups. Tibolone was administered intraperitoneally. Biomarkers, including Sirtuin (SIRT1), Yes-associated protein (YAP), Tumor necrosis factor (TNF-α), High mobility group box 1 (HMGB1), malondialdehyde (MDA), creatinine, and urea, were assessed. Histopathological examination evaluated renal damage.
Tibolone administration significantly reduced plasma TNF-α, HMGB1, MDA, creatinine, and urea levels compared to the CLP+Saline group. Moreover, Tibolone elevated SIRT1 and YAP levels in kidney tissues. Histopathological examination demonstrated a significant decrease in tubular epithelial necrosis, luminal debris, dilatation, hemorrhage, and interstitial inflammation in Tibolone-treated rats.
This study unveils the protective role of Tibolone against sepsis-induced AKI in rats. The improvements in inflammatory and oxidative biomarkers and histological evidence suggest Tibolone's potential as a therapeutic intervention in sepsis-associated kidney injury. The upregulation of SIRT1 and YAP indicates their involvement in Tibolone's renoprotective mechanisms. Further investigations are warranted to explore Tibolone's translational potential in human sepsis-induced AKI.
脓毒症引起的急性肾损伤(AKI)仍然是重症监护中的一个主要挑战,它极大地导致了发病率和死亡率。替勃龙因其具有神经保护和激素特性而尚未被探索用于 AKI 管理。本研究旨在探讨替勃龙在脓毒症大鼠模型中的保护作用及其涉及 Sirtuin-1(SIRT1)和 Yes-Associated Protein(YAP)的潜在机制。
36 只雌性 Wistar 白化大鼠接受盲肠结扎和穿孔(CLP)以诱导脓毒症。它们被随机分为对照组、CLP+生理盐水组和 CLP+替勃龙组。替勃龙通过腹腔内给药。评估了生物标志物,包括 Sirtuin(SIRT1)、Yes-associated protein(YAP)、肿瘤坏死因子(TNF-α)、高迁移率族蛋白 1(HMGB1)、丙二醛(MDA)、肌酐和尿素。组织病理学检查评估了肾脏损伤。
与 CLP+生理盐水组相比,替勃龙给药显著降低了血浆 TNF-α、HMGB1、MDA、肌酐和尿素水平。此外,替勃龙还提高了肾脏组织中的 SIRT1 和 YAP 水平。组织病理学检查显示,替勃龙治疗的大鼠肾小管上皮细胞坏死、管腔碎片、扩张、出血和间质炎症明显减少。
本研究揭示了替勃龙在大鼠脓毒症诱导的 AKI 中的保护作用。炎症和氧化生物标志物的改善以及组织学证据表明,替勃龙可能成为脓毒症相关肾损伤的治疗干预措施。SIRT1 和 YAP 的上调表明它们参与了替勃龙的肾保护机制。需要进一步的研究来探讨替勃龙在人类脓毒症诱导的 AKI 中的转化潜力。